Literature DB >> 18711201

Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

Doru T Alexandrescu, Rebecca McClure, Haleh Farzanmehr, Constantin A Dasanu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18711201     DOI： 10.1200/JCO.2008.18.3525

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

1.  Case: Secondary polycythemia due to pazopanib in patients with metastatic renal cell carcinoma.

Authors:  Nedal Bukhari; Eric Winquist
Journal:  Can Urol Assoc J       Date:  2017-11       Impact factor: 1.862

2.  Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.

Authors:  Andrew X Zhu; Dan G Duda; Marek Ancukiewicz; Emmanuelle di Tomaso; Jeffrey W Clark; Rebecca Miksad; Charles S Fuchs; David P Ryan; Rakesh K Jain
Journal:  Clin Cancer Res       Date:  2010-09-15       Impact factor: 12.531

Review 3.  Hepatocellular carcinoma: Where there is unmet need.

Authors:  Manojkumar Bupathi; Ahmed Kaseb; Funda Meric-Bernstam; Aung Naing
Journal:  Mol Oncol       Date:  2015-06-25       Impact factor: 6.603

Review 4.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

5.  Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.

Authors:  Ronan J Kelly; Olivier Rixe
Journal:  Target Oncol       Date:  2009-10-30       Impact factor: 4.493

6.  Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.

Authors:  Sumita S Bhatta; Kristen E Wroblewski; Kelly L Agarwal; Laura Sit; Ezra E W Cohen; Tanguy Y Seiwert; Theodore Karrison; George L Bakris; Mark J Ratain; Everett E Vokes; Michael L Maitland
Journal:  Oncologist       Date:  2013-07-30

7.  Successful treatment of erythropoietin-producing advanced renal cell carcinoma after targeted therapy using sunitinib: Case report and review of the literature.

Authors:  Kosuke Ueda; Shigetaka Suekane; Katsuaki Chikui; Makoto Nakiri; Fukuko Moriya; Tokumasa Hayashi; Jiro Miyajima; Kei Matsuoka
Journal:  Mol Clin Oncol       Date:  2012-08-03

Review 8.  Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Shaodong Hong; Min Tan; Shouzheng Wang; Shengyuan Luo; Yue Chen; Li Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-06       Impact factor: 4.553

9.  Addition of bevacizumab to temsirolimus in kidney cancer patients.

Authors:  H Boyle; S Négrier
Journal:  Case Rep Oncol       Date:  2011-11-11

10.  Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.

Authors:  Yutaka Fujiwara; Naomi Kiyota; Naoko Chayahara; Akiyuki Suzuki; Yoshiko Umeyama; Toru Mukohara; Hironobu Minami
Journal:  Invest New Drugs       Date:  2011-02-08       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.